Drugs / TQF3250
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07327281 | Dec 2025 → Dec 2026 expected | hyperglycemia | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
聚焦肝病/代谢领域，TQF3250（GLP-1受体激动剂）分别在中国和美国获批2型糖尿病及减重适应症的临床试验，口服剂型具有显著的竞争优势。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQF3250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07327281 ↗ |
| Action | Activate | “selectively activate certain signaling pathways of the GLP-1 receptor” NCT07327281 ↗ |
| Route | Oral | “Oral administration” NCT07327281 ↗ |